story of the week
Safety of Treatment With Ofatumumab for Up to 3.5 Years in Patients With Relapsing Forms of MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
Mult. Scler. 2022 Mar 01;[EPub Ahead of Print], SL Hauser, AH Cross, K Winthrop, H Wiendl, J Nicholas, SG Meuth, PS Giacomini, F Saccà, L Mancione, R Zielman, M Bagger, A Das Gupta, DA Häring, V Jehl, BC Kieseier, R Pingili, D Stoneman, W Su, R Willi, L KapposFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.